Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sensitization Potential of Topical SM04755 Solution in Healthy Volunteers
NCT03502434Phase 1Completed
- Sponsor
- Biosplice Therapeutics
- Start
- Sep 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of SM04755 in tendinopathy (6 arms), sponsored by Biosplice Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events at Day 40, Reaction Grade and 1 more. Started Sep 2017; status: completed.
02
Drugs
SM04755
03
Conditions
tendinopathy
Beyond the preview
Go deeper on NCT03502434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03502434.